4EYJ

MAPK13 Complex with inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.102 Å
  • R-Value Free: 0.275 
  • R-Value Work: 0.242 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.

Alevy, Y.G.Patel, A.C.Romero, A.G.Patel, D.A.Tucker, J.Roswit, W.T.Miller, C.A.Heier, R.F.Byers, D.E.Brett, T.J.Holtzman, M.J.

(2012) J.Clin.Invest. 122: 4555-4568

  • DOI: 10.1172/JCI64896
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Increased mucus production is a common cause of morbidity and mortality in inflammatory airway diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. However, the precise molecular mechanisms for pathogenic muc ...

    Increased mucus production is a common cause of morbidity and mortality in inflammatory airway diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. However, the precise molecular mechanisms for pathogenic mucus production are largely undetermined. Accordingly, there are no specific and effective anti-mucus therapeutics. Here, we define a signaling pathway from chloride channel calcium-activated 1 (CLCA1) to MAPK13 that is responsible for IL-13-driven mucus production in human airway epithelial cells. The same pathway was also highly activated in the lungs of humans with excess mucus production due to COPD. We further validated the pathway by using structure-based drug design to develop a series of novel MAPK13 inhibitors with nanomolar potency that effectively reduced mucus production in human airway epithelial cells. These results uncover and validate a new pathway for regulating mucus production as well as a corresponding therapeutic approach to mucus overproduction in inflammatory airway diseases.


    Organizational Affiliation

    Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Mitogen-activated protein kinase 13
A
371Homo sapiensMutation(s): 0 
Gene Names: MAPK13 (PRKM13, SAPK4)
EC: 2.7.11.24
Find proteins for O15264 (Homo sapiens)
Go to Gene View: MAPK13
Go to UniProtKB:  O15264
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
N61
Query on N61

Download SDF File 
Download CCD File 
A
1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-[4-(pyridin-4-yloxy)phenyl]urea
C20 H23 N5 O2
MHSLDASSAFCCDO-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
N61IC50: 82.7 - 619.5 nM (100) BINDINGDB
N61IC50: 620 nM PDBBIND
Experimental Data & Validation

Experimental Data

Unit Cell:
Length (Å)Angle (°)
a = 60.855α = 90.00
b = 69.955β = 90.00
c = 92.807γ = 90.00
Software Package:
Software NamePurpose
PHENIXmodel building
Blu-Icedata collection
PHENIXrefinement
SCALEPACKdata scaling
HKL-2000data reduction
PHENIXphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2012-12-19
    Type: Initial release